Table 1 Patient characteristics

From: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

Tumor grade

3 ( n =32)

4 ( n =27)

Age, median (years)

45.9

54.3

 Range (years)

24.5–61.7

24.1–70.4

Gender, male

19 (59%)

17 (63)

 Female

13 (41%)

10 (37)

KPS

 90–100

25 (78%)

19 (70)

 70–80

7 (22%)

8 (30)

Diagnosis

 GBM

 

27 (100)

 AA

18 (56%)

 

 AO

13 (41%)

 

 PXA

1 (3%)

 

Time from diagnosis, median (weeks)

189.0

80.4

 Range

11.3–1173.9

24–450

No. of previous PDs

 1

14 (44%)

14 (52)

 2

9 (28%)

8 (30)

 3

9 (28%)

5 (19)

Previous XRT

32 (100%)

27 (100)

Surgery before enrollment

 GTR

3 (9%)

1 (4)

 STR

2 (6%)

0

 Biopsy

2 (6%)

1 (4)

 None

25 (78%)

25 (92)

No. of previous ChemoRx agents

 1

10 (31%)

6 (22)

 2

8 (25%)

8 (30)

 3

7 (22%)

6 (22)

4

7 (22%)

7 (26)

  1. Abbreviations: AA=anaplastic astrocytoma; AO=anaplastic oligodendroglioma; GBM=glioblastoma; GTR=gross total resection; KPS=Karnofsky performance status; PD=progressive disease; PXA=pilocytic xanthroastrocytoma; STR=subtotal resection; XRT=radiotherapy.
  2. The numbers in parentheses refer to percentage unless otherwise indicated.